[Preliminary protocol for systemic administration of XXXX for the treatment of the @entity8511 ].

@entity1 @entity8511 @entity158 @entity2951
AIM: @entity8511 could be considered an expression of atypical @entity158 . The recent neuropathological findings in BMS may suggest the need for alternative therapies. This paper aims to evaluate if systemic @entity2951 could be used for BMS the- rapy. METHODS: Eighty-four BMS @entity1 (19 males and 63 females, aged 36 to 74 years, mean 54.6) were referred to the Oral Medicine and Oral Pathology Department, Dental University Institute, Milan-Bicocca University. They were divided in 2 groups: 1(st) Group: the first group (42 @entity1 ) received 3 capsules of @entity2951 (50 mg of powder of red pepper with 0,25% of @entity2951 ) a day for one month. 2(nd) Group: the control group (42 @entity1 ) received 3 capsules of placebo (empty capsules) a day for one month. The intensity of @entity158 was measured on the visuo-analogical scale VAS. T test of Student was applied to analyse results of VAS. P values of less than 0.05 were interpreted as significant, and the level in confidence intervals was 95%. RESULTS: Significant differences were noted between the two groups at the end of our study (p<0.05). No important side effects were reported. CONCLUSION: Systemic @entity2951 could be considered a successful therapeutical approach for BMS @entity1 .
